Fremanezumab in real-life clinical practice: specialized headache center experience

Fremanezumab in real-life clinical practice: specialized headache center experience

Anti-CGRP monoclonal antibodies (mAb) have been approved and successfully used in Russia since 2020.Objective: to investigate the efficacy and safety of fremanezumab (FRE) therapy (225 mg monthly or 675 mg quarterly) in real-life clinical practice in patients with migraine who referred to a speciali...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu. E. Azimova, K. V. Skorobogatikh, V. V. Osipova, D. Z. Korobkova, N. V. Vashchenko, E. Z. Mamkhegov, A. S. Galanina, E. A. Guziy
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2024-06-01
Series:	Неврология, нейропсихиатрия, психосоматика
Subjects:	migraine monoclonal antibodies fremanezumab ajovi
Online Access:	https://nnp.ima-press.net/nnp/article/view/2288
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression
by: A.Y. Timokhovich, et al.
Published: (2024-10-01)

A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months
by: Shiho Suzuki, et al.
Published: (2025-06-01)

Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature
by: Máté Héja, et al.
Published: (2025-04-01)

Efficacy and safety of anti-CGRP(r) monoclonal antibodies in real clinical practice: preliminary analysis after three months of therapy
by: N. V. Vashchenko, et al.
Published: (2021-12-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
by: Armin Scheffler, et al.
Published: (2024-07-01)

Physical activity as a predictor of fremanezumab response in chronic migraine – the Phy-Fre-Mig study
by: Álvaro Sierra-Mencía, et al.
Published: (2025-02-01)

In the era of monoclonal antibodies targeting the calcitonin gene-related peptide pathway, is it still necessary to stop taking excessive pain medication?
by: Renata Gomes Londero
Published: (2025-09-01)

A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
by: Caroline S. Casey, et al.
Published: (2025-04-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01)

Efficacy and continuability of 675 mg fremanezumab administration over 2 years
by: Shohei Yoshida, et al.
Published: (2025-03-01)

Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
by: Austėja Dapkutė, et al.
Published: (2021-12-01)

Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study
by: Charly Gaul, et al.
Published: (2024-10-01)

Migraine treatment: the doors for the future are open, but with caution and prudence
by: Abouch V. Krymchantowski, et al.

Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies
by: Dawn C. Buse, et al.
Published: (2025-05-01)

Monoclonal antibodies against Mycobacterium tuberculosis, detecting the antigen in urine of the pulmonary tuberculosis patients
by: A. V. Onyan, et al.
Published: (2016-02-01)

New specific migraine prevention: monoclonal antibodies against calcitonin gene-related peptide and its receptor
by: K. Ryliškienė, et al.
Published: (2019-12-01)

Headache and epilepsy: prevalence and clinical variants
by: V. V. Osipova, et al.
Published: (2023-05-01)

Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment
by: Marcin Straburzyński, et al.
Published: (2025-04-01)

Longitudinal assessment of migraine burden in resistant and refractory migraine – Data from the prospective REFINE study
by: Umberto Pensato, et al.
Published: (2025-08-01)

Efficacy of monoclonal antibodies against CGRP in migraine patients with fibromyalgia comorbidity: a retrospective monocentric observational study
by: Marina de Tommaso, et al.
Published: (2025-05-01)

Comprehensive preventive treatments for episodic migraine: a systematic review of randomized clinical trials
by: María-Karina Vélez-Jiménez, et al.
Published: (2025-08-01)

Effectiveness and Safety of CGRP-Targeted Therapies Combined with Lifestyle Modifications for Chronic Migraine in Korean Pediatric Patients: A Retrospective Study
by: Ji-Hoon Na, et al.
Published: (2025-05-01)

Influence of Constipation in the Behavior of Circulating Alpha- and Beta-CGRP Levels in Chronic/High-Frequency Migraine Patients After CGRP Monoclonal Antibodies
by: Gabriel Gárate, et al.
Published: (2025-05-01)

Pericranial muscle dysfunction in primary headache and its correction
by: V. V. Osipova
Published: (2010-12-01)

DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2017-04-01)

Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia
by: M. V. Solovev, et al.
Published: (2024-12-01)

The Effect of Fremanezumab on Pain in Patients with Complex Regional Pain Syndrome: Study Protocol of a Randomized, Double-Blind, Proof-of-Concept, Placebo-Controlled Trial
by: Abarajitha Thiyagarajah, et al.
Published: (2025-04-01)

Headache and Depression
by: J Gordon Millichap
Published: (1992-10-01)

Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study
by: Faisal Mohammad Amin, et al.
Published: (2025-07-01)

The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: Monika Remenčiūtė, et al.
Published: (2024-05-01)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
by: Gabriel Taricani Kubota
Published: (2022-08-01)

Cortical Thickness Changes in Migraine Patients Treated with Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Prospective Age- and Sex-Matched Controlled Study
by: Soohyun Cho
Published: (2025-05-01)

Internet use May be associated with the severity of headache in migraine patients: results from a Hungarian tertiary headache center
by: Anett Csáti, et al.
Published: (2025-03-01)

NEW MONOCLONAL ANTIBODY FOR TUMOR-ASSOCIATED PROTEIN PMEPA1 DETECTION
by: V. V. Volkomorov, et al.
Published: (2016-02-01)

Migraine and other headaches in transient ischemic attacks
by: E. R. Lebedeva, et al.
Published: (2019-06-01)

Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2024-02-01)

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
by: Christian Lampl, et al.
Published: (2024-12-01)

Purification of Monoclonal Antibodies Using Chromatographic Methods: Increasing Purity and Recovery
by: Elnazalsadat Jafarzadeh Chehraghi, et al.
Published: (2025-04-01)

Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023-11-01)